Regeneron Pharmaceuticals, Inc.’s employee count grew from around 8,000 positions in 2019 to almost 13,500 in 2023. Alongside this expansion in personnel, the company has doubled its R&D spend – investing $4.4bn in 2023.
Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’
Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline.
